Literature DB >> 30485483

Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study.

Tomoyuki Ohara1,2, Jun Hata2,3,4, Masashi Tanaka5, Takanori Honda2, Hajime Yamakage5, Daigo Yoshida2,3, Takayuki Inoue5, Yoichiro Hirakawa2,4, Toru Kusakabe5, Mao Shibata2,3, Tadashi Teraoka6, Takanari Kitazono3,4, Shigenobu Kanba1, Noriko Satoh-Asahara5, Toshiharu Ninomiya2,3.   

Abstract

OBJECTIVE: To investigate the association between serum soluble triggering receptor expressed on myeloid cells 2 (sTREM2), a soluble type of an innate immune receptor expressed on the microglia, and the risk of dementia.
METHODS: A total of 1,349 Japanese community residents aged 60 and older without dementia were followed prospectively for 10 years (2002-2012). Serum sTREM2 levels were quantified by using an enzyme-linked immunosorbent assay and divided into quartiles. Cox proportional hazards model was used to estimate the hazard ratios (HRs) of serum sTREM2 levels on the risk of dementia.
RESULTS: During the follow-up, 300 subjects developed all-cause dementia; 193 had Alzheimer's disease (AD), and 85 had vascular dementia (VaD). The age- and sex-adjusted incidences of all-cause dementia, AD, and VaD elevated significantly with higher serum sTREM2 levels (all p for trend < 0.012). These associations were not altered after adjustment for confounding factors, including high-sensitive C-reactive protein. Subjects with the highest quartile of serum sTREM2 levels had significantly higher multivariable-adjusted risks of developing all-cause dementia, AD, and VaD than those with the lowest quartile (HR = 2.03, 95% confidence interval [CI] = 1.39-2.97, p < 0.001 for all-cause dementia; HR = 1.62, 95% CI = 1.02-2.55, p = 0.04 for AD; HR = 2.85, 95% CI = 1.35-6.02, p = 0.006 for VaD). No significant heterogeneity in the association of serum sTREM2 levels with the development of dementia was observed among the other risk factor subgroups (all p for heterogeneity > 0.11).
INTERPRETATION: The present findings suggest a significant association between increased serum sTREM2 levels and the risk of developing all-cause dementia, AD, and VaD in the general elderly Japanese population. ANN NEUROL 2019;85:47-58.
© 2018 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30485483     DOI: 10.1002/ana.25385

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  21 in total

1.  Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy.

Authors:  Takayuki Inoue; Satoshi Saito; Masashi Tanaka; Hajime Yamakage; Toru Kusakabe; Akira Shimatsu; Masafumi Ihara; Noriko Satoh-Asahara
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

2.  Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.

Authors:  Grace E Weber; Maria Khrestian; Elizabeth D Tuason; Yvonne Shao; Jagan Pillai; Stephen Rao; Hao Feng; Yadi Zhou; Feixiong Cheng; Tara M DeSilva; Shaun Stauffer; James B Leverenz; Lynn M Bekris
Journal:  J Immunol       Date:  2022-05-06       Impact factor: 5.426

Review 3.  Microglia Biomarkers in Alzheimer's Disease.

Authors:  Peng-Fei Zhang; Hao Hu; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2021-03-12       Impact factor: 5.590

4.  Association Between sTREM2, an Immune Biomarker of Microglial Activation, and Aging-Related Brain Volume Changes in Community-Dwelling Older Adults: A 7-Year Follow-Up Study.

Authors:  Ryuzo Orihashi; Yoshito Mizoguchi; Yoshiomi Imamura; Shigeto Yamada; Akira Monji
Journal:  Front Aging Neurosci       Date:  2021-04-26       Impact factor: 5.750

5.  Elevated serum glycated albumin and glycated albumin : hemoglobin A1c ratio were associated with hippocampal atrophy in a general elderly population of Japanese: The Hisayama Study.

Authors:  Tomoyuki Ohara; Yoshihiko Furuta; Naoki Hirabayashi; Jun Hata; Yoichiro Hirakawa; Takanori Honda; Daigo Yoshida; Mao Shibata; Takanari Kitazono; Toshiharu Ninomiya
Journal:  J Diabetes Investig       Date:  2020-03-01       Impact factor: 4.232

6.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Authors:  Edward N Wilson; Michelle S Swarovski; Patricia Linortner; Marian Shahid; Abigail J Zuckerman; Qian Wang; Divya Channappa; Paras S Minhas; Siddhita D Mhatre; Edward D Plowey; Joseph F Quinn; Cyrus P Zabetian; Lu Tian; Frank M Longo; Brenna Cholerton; Thomas J Montine; Kathleen L Poston; Katrin I Andreasson
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

7.  The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.

Authors:  So-Hee Park; Eun-Hye Lee; Hyung-Ji Kim; Sungyang Jo; Sunju Lee; Sang Won Seo; Hyun-Hee Park; Seong-Ho Koh; Jae-Hong Lee
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

8.  Current status of the certification of long-term care insurance among individuals with dementia in a Japanese community: The Hisayama Study.

Authors:  Tomoyuki Ohara; Daigo Yoshida; Jun Hata; Mao Shibata; Takanori Honda; Yoshihiko Furuta; Naoki Hirabayashi; Takanari Kitazono; Tomohiro Nakao; Toshiharu Ninomiya
Journal:  Psychiatry Clin Neurosci       Date:  2021-02-17       Impact factor: 5.188

Review 9.  New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease.

Authors:  Sun Ah Park; Song Mi Han; Chae Eun Kim
Journal:  Exp Mol Med       Date:  2020-04-13       Impact factor: 8.718

Review 10.  Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Authors:  Masashi Tanaka; Satoshi Saito; Takayuki Inoue; Noriko Satoh-Asahara; Masafumi Ihara
Journal:  Int J Mol Sci       Date:  2020-03-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.